The Patient Pathway: Beginning the Journey with Cognitive Impairment
For many diseases, well-defined diagnostic and care pathways guide patients, doctors, and caregivers through the patient journey. That is not the case for Alzheimer’s. This panel will discuss what that pathway should look like, starting from the moment a patient prepares to discuss their brain health with their doctor, through subsequent referrals to specialists and treatment options, to exploring potential involvement in clinical trials. Key Question: What needs to happen so that people with cognitive impairment have a smooth path to a reliable diagnosis, appropriate treatment, and access to clinical trials?
Meeting Patient Demand for Alzheimer's Treatment
The treatment of Alzheimer’s continues to improve. As new therapies are approved by the FDA, doctors have more options for their patients, leading to better and more patient-centered care. Ideally, a patient who has a concern about their cognition will see their primary care physician, have the confidence to raise the concern, be screened for potential impairment, and if appropriate be referred to a physician with the skill, experience, and infrastructure to consider this patient for a new Alzheimer’s therapy. Key Question: What steps are leading clinicians and health systems taking to ensure that each Alzheimer’s patient who qualifies gets the right drug and in time to make a difference?
Drugs in the Pipeline: What’s Next and the Science Behind It
The biology of Alzheimer’s is complex. This session will cover the latest research at the heart of the amyloid hypothesis, how each new drug in this class is different, and what other innovative solutions are being explored. Key Question: What should all of Us know as we face a disease with very limited treatment options today?
